ENDRA Life Sciences to merge with Noble Africa (Renergen), ASP Isotopes to control combined entity

ENDRA Life Sciences Inc.

ENDRA enters merger with Noble Africa LLC; Merger Sub merges into Noble, with Noble surviving as ENDRA sub.
Concurrent $50M PIPE investment into Noble from ASPI and institutional investors at $6.57/unit.
Post-merger, ENDRA renamed Noble Africa Inc.; dual-class stock with Class B having 10 votes/share controlled by ASPI.
Board set at 7 directors: 5 Noble designees, 1 ENDRA designee, CEO; classified board.
Closing conditions include ENDRA having $3.8M cash, stockholder approval, SEC registration, and DFC consent.

item 1.01 item 5.01 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.